# PROTAGONIST THERAPEUTICS, INC. (PTGX) FY2026 Q2 P&L / Income Statement

- Company: PROTAGONIST THERAPEUTICS, INC. (PTGX)
- Period: 2026-04-01 to 2026-06-30
- Filing: Q2 FY2026 10-Q, filed 2026-08-05, accession number 0001104659-26-091123
- Page: https://plicit.ai/financials/ptgx/fy2026-q2-income-statement
- Chart image: https://plicit.ai/charts/ptgx-fy2026-q2-income-statement-sankey.png

## Chart details

Income statement for 2026-04-01 through 2026-06-30. Consolidated revenue, costs and expenses.

- **License and collaboration revenue**: 213,475,000 US dollars
- **Total operating expenses**: 54,709,000 US dollars
- **Income (loss) from operations**: 158,766,000 US dollars
- **Other income (expense), net (calculated)**: 6,348,000 US dollars
- **Income (loss) before income tax expense**: 165,114,000 US dollars
- **Income tax expense**: 2,265,000 US dollars
- **Net income (loss)**: 162,849,000 US dollars
- **Undisclosed sources**: 213,475,000 US dollars. The filing reports revenue as one line and discloses no sources of it.
- **Total operating expenses**: 54,709,000 US dollars

### Chart connections

- Revenue minus operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.